Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma

par Luke, Jason J.
Publié dans Oncologist (2019)

Considering adjuvant therapy for stage II melanoma

par Poklepovic, Andrew S., Luke, Jason J.
Publié dans Cancer (2019)

Dendritic cells, the T cell-inflamed tumor microenvironment and immunotherapy treatment response

par Garris, Christopher S., Luke, Jason J.
Publié dans Clin Cancer Res (2020)

Improving Quality and Addressing the Rising Costs of Cancer Care: Two Birds, One Stone

par Luke, Jason, Mirkin, Joshua, Bach, Peter
Publié 2011

Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma

par Luke, Jason J., Schwartz, Gary K.
Publié 2013

Advances in the Systemic Treatment of Cutaneous Sarcomas

par Luke, Jason J, Keohan, Mary-Louise
Publié 2012

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

par Luke, Jason J., Hodi, F. Stephen
Publié 2013

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

par Luke, Jason J, Ott, Patrick A
Publié 2014

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

par Luke, Jason J., Ott, Patrick A.
Publié dans Oncotarget (2015)

Mechanistic and pharmacologic insights on immune checkpoint inhibitors

par Sweis, Randy F., Luke, Jason J.
Publié dans Pharmacol Res (2017)

The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development

par Olson, Daniel J, Luke, Jason J
Publié dans Immunotherapy (2019)

Improving therapy in metastatic uveal melanoma by understanding prior failures

par Olson, Daniel J., Luke, Jason J.
Publié dans Oncoscience (2020)

Toll-Like Receptor 9 Agonists in Cancer

par Karapetyan, Lilit, Luke, Jason J, Davar, Diwakar
Publié dans Onco Targets Ther (2020)

Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types

par Bao, Riyue, Stapor, Daniel, Luke, Jason J.
Publié dans Genome Med (2020)

Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis

par Labadie, Brian W., Bao, Riyue, Luke, Jason J.
Publié dans Clin Cancer Res (2018)

PD-1 Blockade in Chinese versus Western Patients with Melanoma

par Shoushtari, Alexander N., Bao, Riyue, Luke, Jason J.
Publié dans Clin Cancer Res (2020)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

par Trojaniello, Claudia, Luke, Jason J., Ascierto, Paolo A.
Publié dans Front Oncol (2021)

ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19

par Bao, Riyue, Hernandez, Kyle, Huang, Lei, Luke, Jason John
Publié dans J Immunother Cancer (2020)

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a ran...

par Luke, Jason J., Zha, Yuanyuan, Matijevich, Karen, Gajewski, Thomas F.
Publié dans J Immunother Cancer (2016)

High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery

par Zielinski, Jessica M., Luke, Jason J., Guglietta, Silvia, Krieg, Carsten
Publié dans Front Immunol (2021)